Immune checkpoint inhibition in sarcomas: time to be histology-specific?

Affiliations

¹ Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, UK.
² The Institute of Cancer Research, London, UK.
³ Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK.
⁴ Orthopaedic Research Institute, West China Hospital, Sichuan University, 610041 Sichuan, China. Electronic address: tucq@scu.edu.cn.

Comment

Andrea Napolitano et al. Lancet Oncol. 2022 Sep.

. 2022 Sep;23(9):1111-1112.

doi: 10.1016/S1470-2045(22)00500-9.

¹ Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, UK.
² The Institute of Cancer Research, London, UK.
³ Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK.
⁴ Orthopaedic Research Institute, West China Hospital, Sichuan University, 610041 Sichuan, China. Electronic address: tucq@scu.edu.cn.

No abstract available

Conflict of interest statement

We declare no competing interests.

Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial.
Somaiah N, Conley AP, Parra ER, Lin H, Amini B, Solis Soto L, Salazar R, Barreto C, Chen H, Gite S, Haymaker C, Nassif EF, Bernatchez C, Mitra A, Livingston JA, Ravi V, Araujo DM, Benjamin R, Patel S, Zarzour MA, Sabir S, Lazar AJ, Wang WL, Daw NC, Zhou X, Roland CL, Cooper ZA, Rodriguez-Canales J, Futreal A, Soria JC, Wistuba II, Hwu P. Somaiah N, et al. Lancet Oncol. 2022 Sep;23(9):1156-1166. doi: 10.1016/S1470-2045(22)00392-8. Epub 2022 Aug 4. Lancet Oncol. 2022. PMID: 35934010 Clinical Trial.